Prostatectomy News and Research

RSS

Watchful waiting in prostate cancer becoming more popular

In 2010, the US National Comprehensive Cancer Network guidelines suggested that patients with stable and low-risk prostate cancers could be managed with active surveillance or watchful waiting (AS/WW). AS/WW was considered to be a safe and effective alternative to aggressive surgery to remove the prostate and radiation therapy.

11 Feb 2019

CMR Surgical partners with Nicholson Center to launch U.S.-based training program for Versius

The CMR high-tech surgical training facility is the first in the US to train surgeons with the next-generation robotic system, Versius.

13 Dec 2018

Surgical treatment unnecessary for many prostate cancer patients

Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian men with prostate cancer for 29 years. The results are now published in The New England Journal of Medicine.

12 Dec 2018

LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data

Interstitial brachytherapy uses slightly radioactive particles implanted into the prostate to deliver radiation directly to the tumour (low-dose-rate, LDR).

20 Nov 2018

Study uses gold nanoparticles to remove prostate cancer cells

A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth). It is the first trial of its kind in the world.

9 Nov 2018

$New guideline supports hypofractionated radiation therapy for men with prostate cancer$

New guideline supports hypofractionated radiation therapy for men with prostate cancer

Three prominent medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men.

12 Oct 2018

Prostatectomy plus radiotherapy associated with greater survival in prostate cancer patients

High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other.

25 Sep 2018

Researchers develop technology to help deconstruct surgeons' robotic surgery skills

Researchers from the Keck School of Medicine of USC are looking to technology to help deconstruct expert surgeons' robotic surgery skills so they can create an objective, standardized way to train the next generation of surgeons.

11 Sep 2018

High-fat diet and systemic inflammation contribute to progression of prostate cancer

Osaka University-led study shows how a high-fat diet and systemic inflammation contribute to prostate cancer progression

18 Jul 2018

Landmark study shows robotic surgery is as effective as open surgery in treating bladder cancer

Robotic surgery is as effective as traditional open surgery in treating bladder cancer, according to a landmark study published in the journal Lancet.

12 Jul 2018

Bayshore Medical Center now offers robotic-assisted surgery to community

Hackensack Meridian Health Bayshore Medical Center in Holmdel is now home to the da Vinci Si Surgical system, bringing advanced technology in surgery to the medical center's operating room and to the community.

2 Jul 2018

Study: Men tolerate stress urinary incontinence for years before seeking medical help

Men often tolerate stress urinary incontinence for more than two years before seeking medical help - and one-third put up with it for more than five years, making it important for doctors to check for this problem, a new study from UT Southwestern researchers advises.

25 Jun 2018

AAA doses first patients in two clinical studies with PSMA-R2 for prostate cancer

Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen, which is commonly expressed on prostate cancer cells.

22 Jun 2018

New study shows declines in prostate cancer screening, diagnoses and treatment

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed.

21 May 2018

Prostate cancer on the rise and detected late in the UK finds report

As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.

9 Apr 2018

Newly expanded program at Rush offers relief from pelvic floor problems

Trouble with urine or bowel control, bladder pain, recurring urinary tract infections, constipation and other sexual function issues frequently can be traced to a dysfunctional pelvic floor -- the layer of muscles that support the bladder and bowel in men, and bladder, bowel and vagina in women.

6 Apr 2018

Measurement of tumor's metabolic activity could help determine prostate cancer prognosis

A new approach to analyzing prostate gland tissue may help address a major challenge in treating prostate cancer - determining which tumors are unlikely to progress and which could be life threatening and require treatment.

27 Mar 2018

Multimodal treatment approach enhances long-term survival in men with metastatic prostate cancer

UCLA researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.

5 Mar 2018

New PET imaging agent allows early detection of prostate cancer relapse

An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level).